Assembly Bio's HBV drug shows strong efficacy in Phase 1b trial, sets stage for licensing decision with Gilead Sciences.

Assembly Biosciences' (ASMB) HBV drug, ABI-4334, showed strong efficacy in a Phase 1b trial with HBV DNA reductions of 2.9 log10 IU/mL at 150 mg and 3.2 log10 IU/mL at 400 mg. The drug was well-tolerated, and pharmacokinetics support once-daily oral dosing. A licensing decision for Gilead Sciences is pending. ASMB is a clinical-stage biotech focused on small-molecule therapies for serious viral infections.